News Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2026-02-06 EST			5-day change	1st Jan Change
152.50 ^USD	+2.10%		+7.43%	+24.25%

02-06	Sector Update: Health Care Stocks Rise Late Afternoon	MT
02-06	Sector Update: Health Care	MT

02-06	Sector Update: Health Care Stocks Rise Late Afternoon	MT
02-06	Sector Update: Health Care	MT
02-06	Diary - U.S. earnings week ahead	RE
02-06	Fda Approves Label Update for Kite's Yescarta®? for Relapsed/Refractory Primary Central Nervous System Lymphoma	CI
02-06	Gilead Sciences Says Yescarta Won FDA Label Update, Removing Use Limits for Relapsed CNS Lymphoma Patients	MT
02-06	Fda approves label update for Kite's Yescarta® for relapsed/refractory primary central nervous system lymphoma	RE
02-06	FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma	BU
02-04	Arcellx, Inc. Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder	CI
01-30	Leerink Partners Adjusts Gilead Sciences Price Target to $146 From $114, Maintains Outperform Rating	MT
01-29	Gilead Sciences Insider Sold Shares Worth $1,398,911, According to a Recent SEC Filing	MT
01-29	TD Cowen Adjusts Gilead Sciences Price Target to $145 From $125, Maintains Buy Rating	MT
01-28	Wolfe Adjusts Price Target on Gilead Sciences to $155 From $150, Maintains Outperform Rating	MT
01-27	US names HIV, arthritis drugs for next Medicare price talks	RE
01-27	Cms announces selection of drugs for third cycle of the Medicare drug price negotiation program	RE
01-27	Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026	BU
01-27	Citigroup Adjusts Price Target on Gilead Sciences to $156 From $140, Maintains Buy Rating	MT
01-27	Gilead Sciences Insider Sold Shares Worth $15,611,400, According to a Recent SEC Filing	MT
01-26	UBS Adjusts Price Target on Gilead Sciences to $155 From $145, Maintains Buy Rating	MT
01-26	Janux Therapeutics, Inc. Announces Chief Medical Officer Changes	CI
01-26	BMO Capital Adjusts Price Target on Gilead Sciences to $150 From $135, Maintains Outperform Rating	MT
01-21	Gilead Sciences Reports Publication of Phase 3 Trial Results of Trodelvy and Keytruda for Breast Cancer	MT
01-21	New England Journal of Medicine publishes phase 3 Ascent-04/Keynote-D19 results	RE
01-21	New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer	BU
01-21	Gilead Sciences, Inc. Announces New England Journal of Medicine Publishes Phase 3 ASCENT-04/KeyNOTE-D19 Results Supporting Trodelvy®? Plus Keytruda®? as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-Negative Breast Cancer	CI
01-21	Gilead Sciences Insider Sold Shares Worth $617,500, According to a Recent SEC Filing	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Time To Grow PFL Fanbase, Revenue: CEO John Martin

July 11, 2025 at 04:09 am